Low Penetrance, Broad Resistance, and Favorable Outcome of Interleukin 12 Receptor β1 Deficiency

Claire Fieschi(Inserm), Stéphanie Boisson‐Dupuis(Inserm), Émilie Catherinot(Inserm), Jacqueline Feinberg(Inserm), Jacinta Bustamante(Inserm), Adrien Breiman(Inserm), Frédéric Altare(Inserm), Richard Baretto(Immune Regulation (United Kingdom)), Françoise Le Deist, Samer Kayal(Inserm), Hartmut Koch(Marienhospital Stuttgart), Darko Richter(University Hospital Centre Zagreb), Martin Brezina, Güzide Aksu(Ege University), P. Wood(Leeds General Infirmary), Suliman Aljumaah(King Faisal Specialist Hospital & Research Centre), Miquel Raspall‐Chaure(Vall d'Hebron Hospital Universitari), Alberto José da Silva Duarte(Universidade de São Paulo), David Tuerlinckx(UCLouvain), J L Virelizier(Institut Pasteur), Alain Fischer(Hôpital Necker-Enfants Malades), Andrea M. Enright(Stanford Medicine), Jutta Bernhöft(Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie), Aileen M. Cleary(Stanford Medicine), Christiane Vermylen(Cliniques Universitaires Saint-Luc), Carlos Rodríguez‐Gallego(Hospital Universitario de Gran Canaria Doctor Negrín), Graham Davies(Great Ormond Street Hospital), Renate Blütters‐Sawatzki(Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie), Claire-Anne Siegrist(University Hospital of Geneva), Mohammad Ehlayel(Hamad Medical Corporation), Vas Novelli(Great Ormond Street Hospital), W. Haas(Heidelberg University), Jacob Levy(Ben-Gurion University of the Negev), Joachim Freihorst(Medizinische Hochschule Hannover), Sami Al-Hajjar(King Faisal Specialist Hospital & Research Centre), David Nadal(University Children's Hospital Zurich), Dewton de Moraes Vasconcelos(Universidade de São Paulo), Olle Jeppsson, Necil Kütükçüler(Ege University), Klára Frecerová, Isabel Caragol(Vall d'Hebron Hospital Universitari), David A. Lammas(Immune Regulation (United Kingdom)), Dinakantha Kumararatne(Addenbrooke's Hospital), Laurent Abel(Inserm), Jean‐Laurent Casanova(Hôpital Necker-Enfants Malades)
The Journal of Experimental Medicine
February 17, 2003
Cited by 303Open Access
Full Text

Abstract

The clinical phenotype of interleukin 12 receptor beta1 chain (IL-12Rbeta1) deficiency and the function of human IL-12 in host defense remain largely unknown, due to the small number of patients reported. We now report 41 patients with complete IL-12Rbeta1 deficiency from 17 countries. The only opportunistic infections observed, in 34 patients, were of childhood onset and caused by weakly virulent Salmonella or Mycobacteria (Bacille Calmette-Guérin -BCG- and environmental Mycobacteria). Three patients had clinical tuberculosis, one of whom also had salmonellosis. Unlike salmonellosis, mycobacterial infections did not recur. BCG inoculation and BCG disease were both effective against subsequent environmental mycobacteriosis, but not against salmonellosis. Excluding the probands, seven of the 12 affected siblings have remained free of case-definition opportunistic infection. Finally, only five deaths occurred in childhood, and the remaining 36 patients are alive and well. Thus, a diagnosis of IL-12Rbeta1 deficiency should be considered in children with opportunistic mycobacteriosis or salmonellosis; healthy siblings of probands and selected cases of tuberculosis should also be investigated. The overall prognosis is good due to broad resistance to infection and the low penetrance and favorable outcome of infections. Unexpectedly, human IL-12 is redundant in protective immunity against most microorganisms other than Mycobacteria and Salmonella. Moreover, IL-12 is redundant for primary immunity to Mycobacteria and Salmonella in many individuals and for secondary immunity to Mycobacteria but not to Salmonella in most.


Related Papers

No related papers found

Powered by citation graph analysis